InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
InspireMD (Nasdaq: NSPR) reported 30-day results from its CGUARDIANS II trial of the CGuard Prime 80 cm implant for TCAR. In 50 high-risk patients, acute device success was 100% (50/50) with no deaths, strokes, MI, or stent thrombosis at 30 days. The company said an FDA PMA supplement is under review, with potential approval in H2 2026.
How this was made
The 30-second read
Why it matters
The release provides new 30-day clinical outcomes from CGUARDIANS II and reiterates management’s expectation for potential FDA approval in H2 2026, which could expand the company’s addressable market from CAS to include TCAR.
Market read
Traders may reprice NSPR’s probability-weighted TCAR expansion as the company moves through FDA review, using the 30-day zero-MACE safety signal as a key near-term catalyst.
What to watch
The implant is still investigational in the US and the PMA supplement is under review—approval timing and label scope (and any post-approval requirements) are key swing factors for valuation.
Background
InspireMD is seeking FDA approval for a PMA supplement covering the CGuard Prime 80cm implant for TCAR, building on its existing carotid stent system and using the ENROUTE neuro-protection system.
Ticker impact
InspireMD reported 30-day CGUARDIANS II outcomes for the CGuard Prime 80cm implant in TCAR and expects potential FDA approval in H2 2026.
Bias toward bullish near-term sentiment as traders price-in probability of expanded TCAR addressable market; upside tempered by single-arm design and FDA review risk.
The article discloses concrete 30-day clinical endpoints (100% acute device success; zero deaths/strokes/MI; no thrombosis) plus management’s H2 2026 approval anticipation, which can re-rate the TAM narrative, but it remains investigational and regulatory timing is uncertain.
Market effects
Supports the broader TCAR carotid-stent competitive narrative by strengthening the case for device expansion beyond CAS.
Primarily US regulatory/commercial impact tied to FDA PMA review and US TCAR procedure volumes.
Limited direct global impact in the text; could influence future international regulatory discussions if US approval follows.
Counterpoint
Single-arm, prospective pivotal study with 50 patients may not translate to broad real-world effectiveness; FDA could request additional data despite strong 30-day safety.
Key entities
- companyInspireMD, Inc.
Developer of the CGuard Prime carotid stent system; reported CGUARDIANS II 30-day outcomes and expects potential H2 2026 FDA approval for TCAR use.
- regulatorFDA
Under review for the PMA supplement related to CGuard Prime 80cm implant use in TCAR procedures.
- clinical_trialCGUARDIANS II
Prospective, multi-center, single-arm pivotal study evaluating acute device success/technical success for the CGuard Prime 80cm in high-risk TCAR patients.
